Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1994-02-09
1997-07-15
Weddington, Kevin E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514381, 514457, 514510, 514579, 514650, 514673, A61K 31495, A61K 3142, A61K 3135, A61K 3121
Patent
active
056483554
ABSTRACT:
A method for treating endogenous, painful gastrointestinal conditions of non-inflammatory, non-ulcerative origin, such as abdominal migraine and irritable bowel syndrome, entails administering a pharmacologically effective amount of a mast cell degranulation-blocking agent.
REFERENCES:
patent: 4507321 (1985-03-01), Raisfeld
patent: 4843074 (1989-06-01), Rzeszotarski et al.
patent: 5057322 (1991-10-01), Frost
patent: 5250529 (1993-10-01), Theoharides
Pothoulakis et al., "CP-96,345, a substance P antagonist, inhibits rat intestinal responses to Clostridium difficile toxin A but no cholera toxin", Proc. Natl. Acad. Sci., vol. 91, pp. 947-951, Feb. 1994.
Pothoulakis et al., "Ketotifen Inhibits Clostridium difficile Toxin A-Induced Enteritis in Rat Ileum", Gastroenterology 1993, vol. 105, pp. 701-707.
Castagliuolo et al., "Neuronal Involvement In The Intestinal Effects Of Clostridium difficile Toxin A And Vibrio Cholera Enterotoxin In Rat Ileum", Gastroenterology, 104:A677, 104:A679, 1993.
Weston, et al. "Terminal Ileal Mucosal Mast Cells in Irritable Bowel Syndrome", Digestive Diseases and Sciences, 38(9):1590-1595, 1993.
Read, "Irritable Bowel Syndrome (IBS)--Definition and Pathophysiology", Scand. Jrn. Gastroenterol., 130:7-13, 1987.
Stefanini, et al. "Oral Disodium Cromoglycate Treatment on Irritable Bowel Syndrome: An Open Study on 101 Subjects with Diarrheic Type", Am. Jrnl. of Gastroenterology, 87(1):55-57, 1992.
Martin, et al. "Comparison of the Inhibitory Effects of Spermine, Papaverine and Adrenaline Upon Isolated Segments . . . ", Clin. & Exper. Pharma. & Physiology, 13:87-90, 1986.
Cartagena, et al. "Inhibition of Mast Cell Degranulation by Natural Polyamines", Federation Proceedings, 45:1648, 1986.
Page, et al. "Treatment of the Irritable Syndrome with Bentyl.RTM. (Dicyclomine Hydrochloride)", Clin. Gastroenterol., 3:153-156, 1981.
Aihara, et al. "Polyamine Inhibition of Gastric Ulceration and Secretion in Rats", Biochemical Pharmacology, 32(11):1733-1736, 1983.
McCormack, et al. "Polyamines are necessary for cell migration by a small intestinal crypt cell line", Am. Jrnl. of Physiology, 264(2):G367-G374, 1993.
Auricchio, et al. "Amines Protect In Vitro the Celiac Small Intestine From the Damaging Activity of Gliadin Peptides", Gastroenterology, 99:1668-1674, 1990.
Stern, et al. "Contribution to pharmacology of spermidine", Glas Srpske Akademije Nauka, 24:43-50, 1971 (See abstract).
Chemical Abstracts; Ferzoco et al., "Counterregulation of a Prokinetic Calcium-Dependent Mechanism by CAMP-Dependent Agents in Isolated Segments of Terminal Ileum"; Abstract No. 119: 41390 (See Abstract).
KOS Pharmaceutical, Inc.
Weddington Kevin E.
LandOfFree
Method of treatment of endogenous, painful gastrointestinal cond does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treatment of endogenous, painful gastrointestinal cond, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treatment of endogenous, painful gastrointestinal cond will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1492487